2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcome
2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2019
Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
Sposito A, Carvalho L, Moura F, Campos-Staffico A, Cintra R, Nadruz W, Almeida O, Quinaglia e Silva J. Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Scientific Reports 2019, 9: 16401. PMID: 31704948, PMCID: PMC6841947, DOI: 10.1038/s41598-019-52111-x.Peer-Reviewed Original ResearchConceptsEuglycemic hyperinsulinemic clampMyocardial infarctionInsulin sensitivityAcute phaseShort-course treatmentInfluence glucose homeostasisAssociated with mortalityDose-dependent mannerStable patientsClinical outcomesProspective studyStatinsHyperinsulinemic clampPatientsExperimental modelGlucose homeostasisHOMA2DaysExcess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity
de Lima-Junior J, Virginio V, Moura F, Bertolami A, Bertolami M, Coelho-Filho O, Zanotti I, Nadruz W, de Faria E, de Carvalho L, Sposito A. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition Metabolism And Cardiovascular Diseases 2019, 30: 254-264. PMID: 31753789, DOI: 10.1016/j.numecd.2019.09.017.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessBody mass indexCholesterol efflux capacityReduced cholesterol efflux capacityNon-diabetic individualsNon-obeseHDL-CIncreased values of BMIAtherosclerotic burdenEfflux capacityValues of body mass indexElevation of body mass indexProtective function of HDLIncreased BMIObesity-related declineInhibition of platelet aggregationHigh-density lipoprotein (HDLIncreased atherosclerotic burdenAssociated with carotid intima-media thicknessIncreased HDL-CDecreased HDL concentrationIntima-media thicknessFunction of HDLLipoprotein (HDLPlatelet aggregation inhibition
2013
Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study
Moura F, Dutra-Rodrigues M, Cassol A, Parra E, Zago V, Panzoldo N, Alexandre F, Vieira I, Vendrame F, Virginio V, Castanho V, Danelon M, Nunes V, Leança C, Saraiva F, Coelho O, Nakandakare E, Quintão E, de Faria E, Sposito A. Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study. Chronobiology International 2013, 30: 1011-1015. PMID: 23837747, DOI: 10.3109/07420528.2013.793698.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedAged, 80 and overBiomarkersBrazilChildChild, PreschoolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDyslipidemiasFemaleHumansInfantInfant, NewbornMaleMiddle AgedNonlinear DynamicsPeriodicityPrevalenceRisk FactorsSeasonsSex DistributionSex FactorsTime FactorsTriglyceridesYoung AdultConceptsLDL-CHDL-CLipoprotein cholesterolLipid profileLow-density lipoprotein cholesterolPlasma low-density lipoprotein cholesterolHigh-density lipoprotein cholesterolPrevalence of dyslipidemiaAnalysis of relative riskLipid profile parametersVariation of lipid profilePrimary care centersLipid parametersRate of goal achievementCross-sectional analysisConsecutive individualsRelative riskCardiovascular diseaseCare centerHealth checkupsMiddle-aged adultsTriglyceridesBiological rhythmsPreliminary dataPrevalence